LGALS3 and hepatocellular carcinoma: However, silencing LGALS3 in HCC cells or treated mice with LGALS3‐neutralizing antibodies dramatically decreased the bone metastatic capability and osteolytic destructive effect of HCC cells (Figure 3B,C and Figure S3J–L, Supporting Information), indicating that LGALS3 was a vital target to inhibit HCC‐BM.